 The study assesses Mongolia's drug reimbursement system, revealing the decisions regarding drug registration were based on quality, safety, efficacy, and economic considerations. A total of 12.1% of total health expenditure was spent on patient reimbursement of essential drugs, with the highest reimbursed drugs being cardiovascular drugs. Health insurance is compulsory for all citizens and ensured patients have access to reimbursed drugs. However, the decision-making process was limited by various barriers, including lack of evidence-based data regarding efficacy and comparative cost effectiveness analysis of drugs and decisions regarding reimbursement. The study suggests that more evidence-based research studies are required in Mongolia to evaluate and improve the effectiveness of drug pricing and reimbursement policies. This article was authored by Gerald Tuya Dorj, Bruce Underland, Tsetsegma Sanjav and others. We are article.tv. Links in the description below.